** Brokerage Leerink Partners raises price target of healthcare conglomerate CVS Health CVS.N to $86 from $83
** New PT implies a 29% upside to the stock's last close
** Brokerage says that the Health Care Benefits business is the main source of earnings growth and that CVS is well-positioned here, especially in Medicare Advantage
** Brokerage believes that some risks remain in Medicaid and ACA/Obamacare plans, but overall, CVS has less exposure to these problem areas compared to peers
** CVS Caremark, its pharmacy benefits management unit is expected to perform well, driven by specialty drugs and higher usage - Leerink
** Leerink says prescription sales in the retail pharmacy segment is strong and CVS is gaining share, though sales of other products are still weak because consumers are spending less
** As of last close CVS stock up 48.5% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。